ArticleClinical and experimental immunology2014
Functional relevance of NLRP3 inflammasome-mediated interleukin (IL)-1β during acute allergic airway inflammation.
Article in Clinical and experimental immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 55 citations in OpenAlex.
- Maternal Aspartame Exposure Induces Neonatal Pulmonary Metabolic Dysregulation and Redox Imbalance: A Multiomics Investigation of Gut Microbiota-Host Interactions.Journal of agricultural and food chemistry · 2025Article
- NLRP3 regulates epithelial barrier integrity and protects from airway hyperresponsiveness in experimental allergic asthma.Frontiers in immunology · 2025Article
- Benzo[a]pyrene exacerbates allergen-induced airway inflammation through NLRP3-dependent dendritic cell activation and pathogenic T helper cell polarization.Frontiers in immunology · 2025Article
- Pyroptosis in asthma: inflammatory phenotypes, immune and non-immune cells, and novel treatment approaches.Frontiers in pharmacology · 2024Review
- NLRP3 promotes allergic responses to birch pollen extract in a model of intranasal sensitization.Frontiers in immunology · 2024Article
- Interleukin 1β Mediates the Pathogenesis of Nasal Mucosal Epithelial Barrier Dysfunction in Allergic Rhinitis.Journal of inflammation research · 2024Article
- Canonical and non-canonical functions of NLRP3.Journal of advanced research · 2023Review
- Programmed Cell Death in Asthma: Apoptosis, Autophagy, Pyroptosis, Ferroptosis, and Necroptosis.Journal of inflammation research · 2023Review
- IL-1Mediators of inflammation · 2023Review
- Effects of Z-VaD-Ala-Asp-Fluoromethyl Ketone (Z-VAD-FMK) and Acetyl-Asp-Glu-Val-Asp-Aldehyde(Ac-DEVD-CHO) on Inflammation and Mucus Secretion in Mice Exposed to Cigarette Smoke.International journal of chronic obstructive pulmonary disease · 2023Article
- A unique presentation of NLRP3-associated autoinflammatory disease: case report.BMC rheumatology · 2022Article
- The systemic immune response due to cholesterol crystal embolization syndrome: a case report.BMC nephrology · 2022Article
- Neutrophils and Asthma.Diagnostics (Basel, Switzerland) · 2022Review
- Biological Treatments and Target Therapies for Pediatric Respiratory Medicine: Not Only Asthma.Frontiers in pediatrics · 2022Article
- NOD-like receptors in asthma.Frontiers in immunology · 2022Review
- Arf6 exacerbates allergic asthma through cell-to-cell transmission of ASC inflammasomes.JCI insight · 2021Article
- FSTL1 aggravates OVA-induced inflammatory responses by activating the NLRP3/IL-1β signaling pathway in mice and macrophages.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Article
- Adoptive Transfer of Immune Cells Into RAG2IL-2Rγ-Deficient Mice DuringFrontiers in immunology · 2021Article
- Innate Immune Responses and Pulmonary Diseases.Advances in experimental medicine and biology · 2021Article
- Inhibition of the Inflammasome Activity of NLRP3 Attenuates HDM-Induced Allergic Asthma.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overall asthmatic symptoms can be controlled with diverse therapeutic agents. However, certain symptomatic individuals remain at risk for serious morbidity and mortality, which prompts the identification of novel therapeutic targets and treatment strategies. Thus, using an adjuvant-free T helper type 2 (Th2) murine model, we have deciphered the role of interleukin (IL)-1 signalling during allergic airway inflammation (AAI). Because functional IL-1β depends on inflammasome activation we first studied asthmatic manifestations in specific inflammasome-deficient [NACHT, LRR and PYD domains-containing protein 3 (NLRP3(-/-) ) and apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC(-/-) )] and IL-1 receptor type 1(-/-) (IL-1R1(-/-) ) mice on the BALB/c background. To verify the onset of disease we assessed cellular infiltration in the bronchial regions, lung pathology, airway hyperresponsiveness and ovalbumin (OVA)-specific immune responses. In the absence of NLRP3 inflammasome-mediated IL-1β release all symptoms of AAI were reduced, except OVA-specific immunoglobulin levels. To address whether manipulating IL-1 signalling reduced asthmatic development, we administered the IL-1R antagonist anakinra (Kineret®) during critical immunological time-points: sensitization or challenge. Amelioration of asthmatic symptoms was only observed when anakinra was administered during OVA challenge. Our findings indicate that blocking IL-1 signalling could be a potential complementary therapy for allergic airway inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.